Month: July 2020

BRIDGEWATER, N.J., July 13, 2020 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (NASDAQ: SNCR), a global leader and innovator in cloud, messaging, digital, and IoT platforms and products, today announced it will report its second quarter 2020 financial results before the U.S. financial markets open on Monday, August 10, 2020.Synchronoss will host a conference call at 8:00 a.m. (ET) that morning to discuss the financial results. The following are access numbers to join the call:Please click the following link to join the webinar:https://synchronoss.zoom.us/j/99626412696?pwd=bDJQRlF6MjNoN3c3amJySHFKemx1dz09 Password: 015747To join by telephone, please dial one of the following numbers based on your location:Following the conference call, an archived webcast of the conference call will be available on the Investor Relations section...

— INFINITY trial is currently enrolling patients with DME, the most common cause of vision loss in people with diabetic retinopathy —REDWOOD CITY, Calif., July 13, 2020 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that the first patient was randomized in the INFINITY clinical trial to evaluate ADVM-022 for the treatment of diabetic macular edema (DME). Diabetes impacts over 30 million people in the United States and over 400 million people globally and is increasing in prevalence. Approximately 5% of adults with diabetes are impacted by DME, a vision-threatening complication of diabetic retinopathy.Arshad M. Khanani, M.D., M.A., principal INFINITY trial investigator, and director of clinical...

PLANO, Texas, July 13, 2020 (GLOBE NEWSWIRE) — via NetworkWire – Sharing Services Global Corporation (OTCQB: SHRG) (“the Company”), formerly Sharing Services, Inc., announces revenues of $131.4 million for the fiscal year ended April 2020, representing a 53% increase of approximately $45.5 million compared to fiscal year 2019 revenues of $85.9 million. This fiscal year sets yet another record for SHRG, as the Company has now reported cumulative sales revenues of over $225 million since the December 2017 launch of products through its Elepreneurs U.S., LLC and Elevacity U.S., LLC subsidiaries.“The last 12 months have been challenging but rewarding for everyone involved with our company. Not only have we demonstrated strong sales growth with our health and wellness products during some difficult times, but as a team we have...

MORRISVILLE, N.C., July 13, 2020 (GLOBE NEWSWIRE) — Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that it has signed a new three-year agreement with Pfizer Inc. (NYSE: PFE) to deliver global product development solutions to support Pfizer’s portfolio. Under the terms of the agreement, Pfizer has the right to extend the term for up to an additional two years. Financial details of the agreement were not disclosed.This agreement builds on a longstanding relationship where Syneos Health has provided insights and expertise across the Clinical and Commercial continuum to support product development. The Company will continue to deliver a broad range of capabilities customized to meet Pfizer’s goals across its portfolio, including full service and FSP solutions.“Our...

Recommendation Based on DMC’s Finding Following the Second Pre-Planned Interim Analysis that the OPTIMA Study is Unlikely to Meet its Primary Efficacy Endpoint of Overall SurvivalCelsion to Conduct a Thorough Analysis of the Unblinded Study Data Before Making a Final DeterminationConference Call to be Held Wednesday, July 15LAWRENCEVILLE, N.J., July 13, 2020 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN), an oncology focused drug-development company, today announced that it has received a recommendation from the independent Data Monitoring Committee (DMC) to consider stopping the global Phase III OPTIMA Study of ThermoDox® in combination with radiofrequency ablation (RFA) for the treatment of hepatocellular carcinoma (HCC), or primary liver cancer.The recommendation was made following the second pre-planned interim safety...

BASKING RIDGE, N.J., July 13, 2020 (GLOBE NEWSWIRE) — Whether you’re into intergalactic bounty hunters, rapping founding fathers, or need to watch a training video for work, there’s no shortage of streaming content available, and the best Video Experience is on Verizon according to Opensignal in its latest Mobile Network Experience Report released today. This is the fourth consecutive time Verizon has been awarded top Video Experience.Verizon Communications Inc. (NYSE, Nasdaq: VZ) was formed on June 30, 2000 and is celebrating its 20th year as one of the world’s leading providers of technology, communications, information and entertainment products and services. Headquartered in New York City and with a presence around the world, Verizon generated revenues of $131.9 billion in 2019. The company offers voice, data and video...

WARREN, N.J., July 13, 2020 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that the first patient has initiated treatment in the Company’s Phase 3 clinical study of INOpulse® inhaled nitric oxide (iNO) therapy for the treatment of COVID-19 (COViNOX) at Banner University Medical Center, within the University of Arizona College of Medicine – Phoenix, under the direction of Dr. Thomas Ardiles, clinical assistant professor and Dr. Marilyn Glassberg, professor of medicine and chief of the Pulmonary, Critical Care and Sleep Division. The Company’s Investigational New Drug application for the Phase 3 study with INOpulse was accepted by the U.S. Food and Drug Administration in May 2020.“Due...

SECAUCUS, N.J., July 13, 2020 (GLOBE NEWSWIRE) — Freshpet, Inc. (NASDAQ: FRPT) (“Freshpet” or the “Company”) today announced it will report results for the second quarter ended June 30, 2020 on Monday, August 3, 2020 after market close.The Company will host a conference call with members of the executive management team to discuss these results with additional comments and details. The conference call is scheduled to begin at 4:30 p.m. ET on Monday, August 3, 2020. To participate on the live call, listeners in North America may dial (877) 407-0792 and international listeners may dial (201) 689-8263.In addition, the call will be broadcast live over the Internet, hosted at the “Investor” section of the Company’s website at www.freshpet.com and will be archived online. A telephonic playback will be available from 7:30 p.m. ET,...

SAN DIEGO, July 13, 2020 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that it will host a key opinion leader (KOL) webinar on envafolimab for the treatment of sarcoma on Friday, July 17, 2020, at 11:00 AM Eastern Time.The KOL webinar will feature a presentation by Robert Maki, M.D., Ph.D., of the University of Pennsylvania School of Medicine, who will discuss the current treatment landscape and unmet medical need in treating patients with sarcoma. Dr. Maki will be available to answer questions at the conclusion...